Skip to main content

Table 1 Summary of demographics of cats participating in the intravenous allogeneic cryopreserved studies

From: Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies

Cat no.

Group

Description

IRIS CKD stage and creatinine (mg/dl)

Treatment

1

Pilot study 1

10 yr MC DSH

IRIS CKD II; creatinine: 2.5

2 × 106 MSCs intravenously × 3 treatments

2

Pilot study 1

15 yr FS DSH

IRIS CKD III; creatinine: 3.5

2 × 106 MSCs intravenously × 3 treatments

3

Pilot study 1

7 yr MC Siamese

IRIS CKD III; creatinine: 4.3

2 × 106 MSCs intravenously × 3 treatments

4

Pilot study 1

12 yr MC DLH

IRIS CKD II; creatinine: 2.4

2 × 106 MSCs intravenously × 3 treatments

5

Pilot study 1

15 yr MC DSH

IRIS CKD II; creatinine: 2.3

2 × 106 MSCs intravenously × 3 treatments

6

Pilot study 1

15 yr FS Siamese

IRIS CKD III; creatinine: 3.5

2 × 106 MSCs intravenously × 3 treatments

7

Pilot study 2

11 yr MC DSH

IRIS CKD II; creatinine: 1.9

4 × 106 MSCs intravenously × 3 treatments

8

Pilot study 2

11 yr FS DSH

IRIS CKD II; creatinine: 2.6

4 × 106 MSCs intravenously × 3 treatments

9

Pilot study 2

18 yr FS DSH

IRIS CKD II; creatinine: 2.8

4 × 106 MSCs intravenously × 3 treatments

10

Pilot study 2

15 yr MC DSH

IRIS CKD II; creatinine: 2.2

4 × 106 MSCs intravenously × 3 treatments

11

Pilot study 2

7 yr MC DSH

IRIS CKD III; creatinine: 3.7

4 × 106 MSCs intravenously × 3 treatments

12

Pilot study 2

15 yr MC DSH

IRIS CKD II; creatinine: 2.3

Iohexol GFR repeatability only

13

Pilot study 2

16 yr MC DSH

IRIS CKD II; creatinine: 2.1

Iohexol GFR repeatability only

14

Pilot study 2

16 yr MC DSH

IRIS CKD II; creatinine: 1.8

Iohexol GFR repeatability only

15

Pilot study 3

9 yr MC DSH

IRIS CKD II; creatinine: 2.6

Enrolled but decompensated before treatment initiated

16

Pilot study 3

15 yr MC Siamese

IRIS CKD II; creatinine: 2.4

4 × 106 MSCs intravenously × 2 treatments before recurrence of previous diabetes

17

Pilot study 3

13 yr MC Siamese

IRIS CKD II; creatinine: 2.7

4 × 106 MSCs intravenously × 3 treatments

18

Pilot study 3

8 yr MC DSH

IRIS CKD II; creatinine: 1.7

4 × 106 MSCs intravenously × 3 treatments

19

Pilot study 3

13 yr MC DSH

IRIS CKD II; creatinine: 2.0

4 × 106 MSCs intravenously × 3 treatments

20

Pilot study 3

15 yr MC DLH

IRIS CKD II; creatinine: 2.3

4 × 106 MSCs intravenously × 3 treatments

21

Pilot study 3

15 yr FS DSH

IRIS CKD III; creatinine: 3.1

4 × 106 MSCs intravenously × 3 treatments

  1. Six cats were enrolled in pilot study 1 and received 2 × 106 cryopreserved adipose-derived mesenchymal stem cells (aMSCs) per infusion. In pilot study 2 eight cats were enrolled; five received 4 × 106 cryopreserved aMSCs per infusion, and three cats received only iohexol clearance studies. In pilot study 3, seven cats were enrolled; five cats received 4 × 106 cryopreserved aMSCs cultured from cryopreserved adipose per infusion; two cats developed unrelated medical conditions and were removed from the trial. CKD, chronic kidney disease; GFR, glomerular filtration rate. MC = male castrated, FS = female spayed, DSH = domestic shorthair, DLH = domestic long hair, IRIS = International Renal Interest Society.
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512